VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 93 filers reported holding VERVE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 4.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $0 | – | 14 | +133.3% | 0.00% | – |
Q1 2024 | $0 | – | 6 | 0.0% | 0.00% | – |
Q4 2023 | $0 | – | 6 | -14.3% | 0.00% | – |
Q3 2023 | $0 | – | 7 | -12.5% | 0.00% | – |
Q2 2023 | $0 | – | 8 | +60.0% | 0.00% | – |
Q1 2023 | $0 | – | 5 | -50.0% | 0.00% | – |
Q4 2022 | $0 | – | 10 | +100.0% | 0.00% | – |
Q3 2022 | $0 | – | 5 | -54.5% | 0.00% | – |
Q2 2022 | $0 | – | 11 | +22.2% | 0.00% | – |
Q1 2022 | $0 | – | 9 | -18.2% | 0.00% | – |
Q4 2021 | $0 | – | 11 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARCH Venture Management, LLC | 2,008,809 | $37,665,169 | 23.26% |
Alphabet Inc. | 10,549,086 | $197,795,362 | 10.63% |
Casdin Capital, LLC | 2,360,571 | $44,260,706 | 3.87% |
MPM BioImpact LLC | 857,940 | $16,086,375 | 3.24% |
Redmile Group, LLC | 1,061,960 | $19,911,750 | 0.76% |
Novo Holdings A/S | 500,000 | $9,375,000 | 0.72% |
ARK Investment Management | 5,150,851 | $96,578,455 | 0.64% |
Avidity Partners Management LP | 878,600 | $16,473,750 | 0.58% |
Nikko Asset Management Americas, Inc. | 2,185,857 | $40,941,102 | 0.43% |
Cormorant Asset Management, LP | 350,000 | $6,562,500 | 0.37% |